The global aminoglycosides market is experiencing steady expansion, reaching a value of USD 1.67 billion in 2024. According to IMARC Group, the market is projected to grow at a CAGR of 2.4% from 2025 to 2033, achieving USD 2.12 billion by 2033. This growth is fueled by rising tuberculosis cases, an aging population vulnerable to bacterial infections, and increasing demand for veterinary and respiratory disease treatments. Additionally, advancements in formulation technologies and the expansion of pharmaceutical infrastructure in emerging markets are contributing to the market's positive trajectory.

Study Assumption Years

• Base Year: 2024
• Historical Years: 2019–2024
• Forecast Years: 2025–2033

Aminoglycosides Market Key Takeaways

• Market Size & Growth: The aminoglycosides market was valued at USD 1.67 billion in 2024 and is expected to reach USD 2.12 billion by 2033, growing at a CAGR of 2.4% during 2025–2033.
• Regional Performance: Asia Pacific leads the market, driven by increased demand for antimicrobial treatments and a growing pharmaceutical industry.
• Product Segmentation: Key products include neomycin, tobramycin, gentamicin, amikacin, paromomycin, streptomycin, kanamycin, and others.
• Route of Administration: Administration methods encompass injectables (parenteral), intra-mammary, topical, oral, and others.
• Application Areas: Applications span veterinary medicine, skin infections, respiratory diseases, urinary tract and pelvic diseases, among others.
• Market Drivers: An aging global population and the prevalence of chronic respiratory infections are significant growth drivers.
• Technological Advancements: Continuous improvements in formulation technologies are enhancing drug efficacy and patient outcomes.

What Are the Major Growth Drivers for the Aminoglycosides Market?

Rising Prevalence of Tuberculosis

The ongoing global burden of tuberculosis (TB) remains a primary catalyst for the aminoglycosides market. These antibiotics, notably streptomycin, play a crucial role in treating TB, especially drug-resistant cases. The World Health Organization continues to report substantial TB caseloads, especially in regions with high prevalence. The persistent need for effective TB management maintains strong demand for aminoglycosides worldwide.

Expansion of Veterinary Applications

The veterinary sector significantly contributes to market momentum. Aminoglycosides are widely employed to address bacterial infections in livestock, supporting both animal health and agricultural productivity. With global demand for animal protein on the rise, especially in developing economies where livestock farming is vital, the use of these antibiotics is expected to see continued growth.

Advancements in Drug Formulation Technologies

Technological innovation is enhancing both the efficacy and safety profile of aminoglycosides. New drug delivery methods—such as liposomal and targeted systems—are improving clinical outcomes and reducing adverse effects. These advancements are particularly important in addressing antibiotic resistance and expanding the therapeutic reach of aminoglycosides.

Market Segmentation

By Product:

• Neomycin: Widely used for topical applications and in combination therapies for gastrointestinal infections.
• Tobramycin: Primarily utilized for treating Pseudomonas aeruginosa infections, especially in cystic fibrosis patients.
• Gentamicin: Commonly prescribed for severe systemic infections and in ophthalmic preparations.
• Amikacin: Effective against multidrug-resistant bacterial strains, often used when other aminoglycosides are ineffective.
• Paromomycin: Used to treat parasitic infections and certain intestinal infections.
• Streptomycin: One of the first antibiotics used to treat TB, still relevant in specific cases.
• Kanamycin: Employed in treating severe infections when other treatments are contraindicated.
• Others: Includes less commonly used aminoglycosides with specific clinical applications.

By Route of Administration:

• Injectables (Parenteral): Preferred for severe infections requiring rapid systemic action.
• Intra-mammary: Used in veterinary medicine, particularly for treating mastitis in dairy cattle.
• Topical: Applied directly to the skin for localized infections.
• Oral: Administered for gastrointestinal infections and when systemic absorption is not required.
• Others: Includes inhalation and other specialized delivery methods.

By Application:

• Veterinary: Ensuring animal health, particularly in livestock, to prevent and treat bacterial infections.
• Skin Infection: Treating bacterial skin conditions, including wounds and ulcers.
• Respiratory Diseases: Managing infections like pneumonia and bronchitis.
• UTI and Pelvic Diseases: Addressing urinary tract infections and pelvic inflammatory diseases.
• Others: Encompasses a range of bacterial infections not classified above.

Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

Which Region Leads the Aminoglycosides Market?

The Asia Pacific region leads the aminoglycosides market, driven by a high prevalence of infectious diseases, expanding pharmaceutical manufacturing, and rising healthcare investment. India and China, in particular, have made significant strides in healthcare infrastructure and antibiotic research, solidifying the region’s dominant market position.

What Are the Recent Developments in the Aminoglycosides Market?

The industry is witnessing ongoing R&D focused on reducing toxicity and enhancing the efficacy of aminoglycosides. Pharmaceutical companies and academic institutions are collaborating to address antibiotic resistance, develop novel derivatives, and introduce improved formulations. These initiatives are expected to further diversify aminoglycosides’ clinical applications and reinforce market growth.

Who Are the Key Players in the Aminoglycosides Market?

Huvepharma NV, Kremoint Pharma Pvt. Ltd., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd, Vega Group company limited, etc.

If you require any specific information that is not currently covered within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, considerations studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyzes, pricing and cost research, and procurement research.